Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: An Analysis from the German Hodgkin Study Group (GHSG)

Dennis A. Eichenauer, MD, Annette Pluetschow, Lena Schroeder, Michael Fuchs, MD, Bastian von Tresckow, MD, Volker Diehl, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2016) 128 (22): 922.

https://doi.org/10.1182/blood.V128.22.922.922

Published: 2016

Journal Articles

Phase II Study of Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group

Dennis A. Eichenauer, MD, Helen Goergen, Annette Pluetschow, Karolin Behringer, MD, Stefanie Kreissl, MD, Paul Bröckelmann, MD, Michael Fuchs, MD, Boris Böll, MD, Bastian von Tresckow, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2015) 126 (23): 2729.

https://doi.org/10.1182/blood.V126.23.2729.2729

Published: 2015

Journal Articles

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

Peter Borchmann, MD, Dennis A. Eichenauer, MD, Annette Pluetschow, Heinz Haverkamp, Stefanie Kreissl, MD, Michael Fuchs, Martin Soekler, Johannes C. Hellmuth, MD, Julia Meissner, MD, Stephan Mathas, Karolin Behringer, MD, Markus Dietlein, Carsten Kobe, Volker Diehl, MD, Andreas Engert

Blood (2015) 126 (23): 580.

https://doi.org/10.1182/blood.V126.23.580.580

Published: 2015

Journal Articles

Treatment of Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): An Analysis from the German Hodgkin Study Group (GHSG)

Dennis A. Eichenauer, MD, Annette Pluetschow, Michael Fuchs, MD, Karolin Behringer, MD, Boris Böll, MD, Bastian von Tresckow, MD, Volker Diehl, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2014) 124 (21): 3058.

https://doi.org/10.1182/blood.V124.21.3058.3058

Published: 2014

Journal Articles

A Phase I Study of Everolimus in Combination with Time-Intensified DHAP (Dexamethasone, High-Dose AraC [Cytarabine], Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Bastian von Tresckow, MD, Annette Pluetschow, Heinz Haverkamp, Vladan Vucinic, MD, Andreas Rank, MD, Max S. Topp, MD, Michaela Feuring-Buske, MD, Carsten Kobe, MD, Georg Kuhnert, MD, Boris Böll, MD, Dennis A. Eichenauer, MD, Stephanie Sasse, MD, Michael Fuchs, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2014) 124 (21): 4433.

https://doi.org/10.1182/blood.V124.21.4433.4433

Published: 2014

Journal Articles

Phase II Study of Rituximab in Newly Diagnosed Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Report From the German Hodgkin Study Group (GHSG)

Dennis A. Eichenauer, MD, Michael Fuchs, MD, Annette Pluetschow, Beate Klimm, MD, Teresa Halbsguth, MD, Boris Böll, MD, Bastian von Tresckow, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2011) 118 (21): 2711.

https://doi.org/10.1182/blood.V118.21.2711.2711

Published: 2011

Journal Articles

Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group

Dennis A. Eichenauer, Michael Fuchs, Annette Pluetschow, Beate Klimm, Teresa Halbsguth, Boris Böll, Bastian von Tresckow, Lucia Nogová, Peter Borchmann, Andreas Engert

Blood (2011) 118 (16): 4363–4365.

https://doi.org/10.1182/blood-2011-06-361055

Published: 2011

Journal Articles

Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

Andreas Engert, MD, Peter Borchmann, MD, Annette Pluetschow, Bastian von Tresckow, Jana Markova, Felicitas Hitz, Zdenek Kral, Richard Greil, MD, Max S Topp, Matthias Villalobos, Josee M. Zijlstra, Martin Soekler, Harald Stein, MD, Hans-Theodor Eich, Rolf-Peter Mueller, Michael Fuchs, Volker Diehl

Blood (2010) 116 (21): 765.

https://doi.org/10.1182/blood.V116.21.765.765

Published: 2010

Journal Articles

Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (Gy) Is the New Standard of Care in the Treatment of Patients with Early-Stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) HD10. Study Supported by the Deutsche Krebshilfe and in Part by the Competence Network Malignant Lymphoma.

Andreas Engert, MD, Volker Diehl, MD, Emeritus, Annette Pluetschow, Hans T. Eich, Richard Herrmann, MD, Bernd Doerken, Lothar Kanz, MD, Richard Greil, Jana Markova, Michael Fuchs, Peter Borchmann, PD, Dr., Hans Konrad Mueller-Hermelink, Rolf Peter Mueller

Blood (2009) 114 (22): 716.

https://doi.org/10.1182/blood.V114.22.716.716

Published: 2009

Journal Articles

Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and Involved Field Radiotherapy (IF-RT) Is Superior to 4 Cycles of ABVD and IFRT in Patients with Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

Peter Borchmann, Andreas Engert, Annette Pluetschow, Michael Fuchs, Jana Markova, Andreas Lohri, Zdenek Kral, Richard Greil, Max Topp, Matthias Villalobos, Jose Zijlstra, MD, Martin Soekler, Harald Stein, Hans Theodor Eich, Rolf Peter Mueller, Volker Diehl

Blood (2008) 112 (11): 367.

https://doi.org/10.1182/blood.V112.11.367.367

Published: 2008

Journal Articles

Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin’s Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG).

Andreas Engert, Annette Pluetschow, Hans T. Eich, Richard Herrmann, Bernd Doerken, Lothar Kanz, Richard Greil, Jana Markova, Beate Pfistner, Andreas Josting, Konrad Mueller-Hermelink, Ralf P. Mueller, Volker Diehl

Blood (2005) 106 (11): 2673.

https://doi.org/10.1182/blood.V106.11.2673.2673

Published: 2005

NARROW

Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: An Analysis from the German Hodgkin Study Group (GHSG)

Phase II Study of Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

Treatment of Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): An Analysis from the German Hodgkin Study Group (GHSG)

A Phase I Study of Everolimus in Combination with Time-Intensified DHAP (Dexamethasone, High-Dose AraC [Cytarabine], Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Phase II Study of Rituximab in Newly Diagnosed Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Report From the German Hodgkin Study Group (GHSG)

Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group

Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin’s Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only